Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Alain Patrick Algazi, Megan Othus, Adil Daud, Janice M. Mehnert, Thach-Giao Truong, Robert Martin Conry, Kari Lynn Kendra, Gary C. Doolittle, Joseph I Clark, Michael J. Messino, Dennis Frederic Moore, Christopher D. Lao, Bryan A. Faller, Rangaswamy Govindarajan, Amy K. Harker-Murray, Luke P. Dreisbach, James Moon, Kenneth F. Grossmann, Roger Lo, Antoni Ribas
Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Fred Hutch Cancer Center, Rutgers Cancer Institute, Kaiser Permanente, Kaiser Permanente Vallejo Medical Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, University of Kansas Medical Center, Loyola University Medical Center, Loyola University Chicago, Cancer Care of Western North Carolina, Cancer Center of Kansas, University of Michigan, Missouri Baptist Medical Center, University of Arkansas for Medical Sciences, Medical College of Wisconsin, Huntsman Cancer Institute, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W3030605145